Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Microbix Biosystms ( (TSE:MBX) ) just unveiled an announcement.
Microbix Biosystems Inc. will release its financial statements and management discussion and analysis for the first quarter of fiscal 2026, covering the period ended December 31, 2025, before markets open on February 12, 2026. On the same day at 10:00 a.m. ET, the company will host a webinar, led by its CEO, CFO and COO and organized by Adelaide Capital, to discuss its fourth-quarter 2025 results, with live access via Zoom and YouTube and a replay to be made available afterward, signaling continued efforts to engage investors and provide transparency around its financial performance and strategic direction.
The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.21 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Spark’s Take on TSE:MBX Stock
According to Spark, TipRanks’ AI Analyst, TSE:MBX is a Neutral.
Microbix Biosystems faces significant challenges in financial performance, with declining revenues and profitability issues. Technical analysis indicates bearish momentum, while valuation metrics are unattractive due to a negative P/E ratio. However, the earnings call provides some optimism with operational improvements and a strong financial position, aiming for recovery in fiscal 2026.
To see Spark’s full report on TSE:MBX stock, click here.
More about Microbix Biosystms
Microbix Biosystems Inc. is a Canadian life sciences company that creates proprietary biological products for the global diagnostics industry, generating C$18.6 million in revenue in its last fiscal year with a workforce of over 120 employees. Its core offerings include antigens for immunoassays and quality assessment products such as QAPs and QUANTDx, which support clinical lab proficiency testing, assay development and validation, and diagnostic workflow quality in more than 30 countries. The company also develops other proprietary products, including the Kinlytic urokinase thrombolytic drug and DxTM reagents for molecular diagnostic testing, and operates under multiple international regulatory accreditations and registrations while being listed on the TSX and OTCQX.
Average Trading Volume: 66,966
Technical Sentiment Signal: Sell
Current Market Cap: C$31.23M
For detailed information about MBX stock, go to TipRanks’ Stock Analysis page.